The firm’s full-service practice in Hong Kong serves clients in all of Goodwin’s key industry verticals, including private equity, technology, life sciences, financial services and real estate. Relocated in 2019, Goodwin’s Hong Kong office sits in the Edinburgh Tower at the Landmark in Hong Kong’s Central business district, a bustling commercial complex located in Central, Hong Kong, and home to many firm clients, including leading financial institutions, private equity houses and other innovative businesses.
Our lawyers in Asia are qualified to practice law in a wide-range of locations including Hong Kong, the People’s Republic of China and Taiwan, India, England, Wales, the U.S. and Canada. Our team is also multilingual and speaks English, Mandarin, Cantonese, Taiwanese and Hindi.
Goodwin’s comprehensive Asia practice is focused on Capital Markets, Corporate, Mergers + Acquisitions, Debt Finance, Private Equity, Private Investment Funds, Venture Capital, Life Sciences, Real Estate and TMT (Technology, Media & Telecom) sectors. As more and more innovative companies and investors seek out Goodwin’s unique platform at the intersection of capital and innovation, our presence in Hong Kong continues to be at heart of our global offering.
We have been named Top Law Firm in Private Equity & Venture Capital by China Business Law Journal in 2017-2018, a Leading International Firm for India-related work by India Business Law Journal since 2008, and a Leading Law Firm for Corporate/M&A (International Firms) in India by Chambers Asia Pacific for many years including recently in 2018.
Market-Leading TMT Practice
Our technology, media and telecom (TMT) practice covers a broad range of corporate transactions. Our deep knowledge in private equity and growth equity, pooled investments and funds, international capital-raising and exchange listing activities, cross-border M&A, as well as joint ventures and restructurings have led to working with well-known technology investors and companies. These include transactions involving AbsolutData, Alibaba Group, BillDesk, Canyon Bridge, Crystal Stream, Didi Chuxing, DST Global, Falcon Edge Capital, Flipkart, FountainVest Partners, Fractal Analytics, Go Jek, Hillhouse Capital, Horizons Ventures, IMAX, JD.com, Koudai, Meituan, Micromax, Olacabs, Quilvest, RRE Ventures, Snapdeal, Tencent, Vy Capital, Xiaomi, Zodius/Advendus Capital, and Zomato.
Life Sciences Across the Full Corporate Lifecycle
Our highly-experienced life sciences lawyers help clients find strategic paths that foster growth and minimize risk across all phases of the corporate lifecycle. We’ve helped serve all legal needs for global life sciences companies with IPOs, mergers and acquisitions, licensing, royalty monetization, strategic guidance and regulatory framework. Our recent Asia experience includes advising on the Hong Kong IPOs of AOBiome and Ascentage, and BeiGene’s U.S. IPO, as well as leading Asia-based private equity funds on their investments in the life sciences sector.